ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Survodutide

Survodutide

Also known as: BI 456906, BI456906

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Survodutide

GLP-1 receptor agonism reduces appetite and improves glycemic control. Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure.

Dosing Information

Half-Life

~5-6 days

Typical Dose

0.3–6 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:
subcutaneous

Benefits

  • Significant weight loss (up to 19% in Phase 2)
  • Potent liver fat reduction and MASH resolution
  • Improved hepatic and metabolic health markers
  • Increased energy expenditure via glucagon signaling

Side Effects

Nausea and gastrointestinal discomfortmild
Diarrhea and vomitingmild
Decreased appetitemild
Transient heart rate increasesmild
Injection site reactionsmild

Mechanism of Action

1

GLP-1 receptor agonism reduces appetite and improves glycemic control

2

Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure

3

Dual action promotes negative energy balance through complementary pathways

Contraindications

Do not use this peptide if any of the following apply:

  • Personal or family history of medullary thyroid carcinoma
  • MEN2 syndrome
  • Severe hepatic impairment
  • History of pancreatitis
  • Pregnancy or breastfeeding

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

Phase 2 data showed survodutide produced up to 18.7% weight loss at 46 weeks and significant improvements in MASH histological endpoints, including fibrosis. The compound demonstrated 83% relative reduction in liver fat content. Phase 3 trials are ongoing for both obesity and MASH indications. Boehringer Ingelheim positions survodutide as a liver-focused metabolic therapy with strong weight loss as a co-benefit.

Frequently Asked Questions

Common questions about Survodutide

UK-Specific Information

Exclusive data points and guidance for UK residents using Survodutide

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok